Hemoglobin

In this Q&A, hematologist Dr. Kwiatkowski discusses the Food and Drug Administration approval of beti-cel (Zynteglo®), a gene therapy for beta thalassemia.

This week’s news roundup features discoveries related to COVID-19’s effect on adolescents, autism screening, telemedicine, and more.

CHOP researchers have developed a potentially safer and more effective gene therapy vector for red blood disorders.

Hematologists have long sought to reactivate fetal hemoglobin as a treatment for children and adults with sickle cell disease (SCD). Researchers at CHOP have manipulated key biological events in adult blood cells to produce a form of hemoglobin normally absent after the newborn period.